Title: Aarkstore - Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2014
1Type 1 Diabetes (Juvenile Diabetes) - Pipeline
Review, H2 2014
Pharmaceuticals Healthcare Market Research
Reports
2Summary
- Type 1 Diabetes (Juvenile Diabetes) - Pipeline
Review, H2 2014, provides an overview of the Type
1 Diabetes (Juvenile Diabetes)s therapeutic
pipeline.This report provides comprehensive
information on the therapeutic development for
Type 1 Diabetes (Juvenile Diabetes), complete
with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism
of action (MoA), route of administration (RoA)
and molecule type, along with latest updates, and
featured news and press releases. It also reviews
key players involved in the therapeutic
development for Type 1 Diabetes (Juvenile
Diabetes) and special features on late-stage and
discontinued projects. - Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team.
3Scope
- - The report provides a snapshot of the global
therapeutic landscape of Type 1 Diabetes
(Juvenile Diabetes)- The report reviews key
pipeline products under drug profile section
which includes, product description, MoA and RD
brief, licensing and collaboration details
other developmental activities - The report
reviews key players involved in the therapeutics
development for Type 1 Diabetes (Juvenile
Diabetes) and enlists all their major and minor
projects- The report summarizes all the dormant
and discontinued pipeline projects - A review of
the Type 1 Diabetes (Juvenile Diabetes) products
under development by companies and
universities/research institutes based on
information derived from company and
industry-specific sources- Pipeline products
coverage based on various stages of development
ranging from pre-registration till discovery and
undisclosed stages- A detailed assessment of
monotherapy and combination therapy pipeline
projects- Coverage of the Type 1 Diabetes
(Juvenile Diabetes) pipeline on the basis of
target, MoA, route of administration and molecule
type- Latest news and deals relating related to
pipeline products
4Reasons to buy
- - Provides strategically significant competitor
information, analysis, and insights to formulate
effective RD development strategies- Identify
emerging players with potentially strong product
portfolio and create effective counter-strategies
to gain competitive advantage- Develop strategic
initiatives by understanding the focus areas of
leading companies- Identify and understand
important and diverse types of therapeutics under
development for Type 1 Diabetes (Juvenile
Diabetes)- Plan mergers and acquisitions
effectively by identifying key players of the
most promising pipeline- Devise corrective
measures for pipeline projects by understanding
Type 1 Diabetes (Juvenile Diabetes) pipeline
depth and focus of Indication therapeutics-
Develop and design in-licensing and out-licensing
strategies by identifying prospective partners
with the most attractive projects to enhance and
expand business potential and Scope- Modify the
therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove
them from pipeline
5Table of Content
- Introduction 7Type 1 Diabetes (Juvenile
Diabetes) Overview 8Therapeutics Development
9Type 1 Diabetes (Juvenile Diabetes) -
Therapeutics under Development by Companies
11Type 1 Diabetes (Juvenile Diabetes) -
Therapeutics under Investigation by
Universities/Institutes 20Type 1 Diabetes
(Juvenile Diabetes) - Pipeline Products Glance
22Type 1 Diabetes (Juvenile Diabetes) - Products
under Development by Companies 26Type 1 Diabetes
(Juvenile Diabetes) - Products under
Investigation by Universities/Institutes 38Type
1 Diabetes (Juvenile Diabetes) - Companies
Involved in Therapeutics Development 40Type 1
Diabetes (Juvenile Diabetes) - Therapeutics
Assessment 135Drug Profiles 147Type 1 Diabetes
(Juvenile Diabetes) - Recent Pipeline Updates
400Type 1 Diabetes (Juvenile Diabetes) - Dormant
Projects 476Type 1 Diabetes (Juvenile Diabetes)
- Discontinued Products 479Type 1 Diabetes
(Juvenile Diabetes) - Product Development
Milestones 480Appendix 489
6List of Tables
- Number of Products under Development for Type 1
Diabetes (Juvenile Diabetes), H2 2014 30Number
of Products under Development for Type 1 Diabetes
(Juvenile Diabetes) - Comparative Analysis, H2
2014 31Number of Products under Development by
Companies, H2 2014 33Number of Products under
Development by Companies, H2 2014 (Contd..1)
34Number of Products under Development by
Companies, H2 2014 (Contd..2) 35Number of
Products under Development by Companies, H2 2014
(Contd..3) 36Number of Products under
Development by Companies, H2 2014 (Contd..4)
37Number of Products under Development by
Companies, H2 2014 (Contd..5) 38Number of
Products under Development by Companies, H2 2014
(Contd..6) 39Number of Products under
Development by Companies, H2 2014 (Contd..7)
40Number of Products under Investigation by
Universities/Institutes, H2 2014 42Comparative
Analysis by Late Stage Development, H2 2014
43Comparative Analysis by Clinical Stage
Development, H2 2014 44Comparative Analysis by
Early Stage Development, H2 2014 45
7List of Figures
- Number of Products under Development for Type 1
Diabetes (Juvenile Diabetes), H2 2014 30Number
of Products under Development for Type 1 Diabetes
(Juvenile Diabetes) - Comparative Analysis, H2
2014 31Number of Products under Development by
Companies, H2 2014 32Number of Products under
Investigation by Universities/Institutes, H2 2014
41Comparative Analysis by Late Stage
Development, H2 2014 43Comparative Analysis by
Clinical Stage Development, H2 2014
44Comparative Analysis by Early Stage Products,
H2 2014 45Assessment by Monotherapy Products, H2
2014 156Assessment by Combination Products, H2
2014 157Number of Products by Top 10 Targets, H2
2014 158Number of Products by Stage and Top 10
Targets, H2 2014 158Number of Products by Top 10
Mechanism of Actions, H2 2014 161Number of
Products by Stage and Top 10 Mechanism of
Actions, H2 2014 161Number of Products by Top 10
Routes of Administration, H2 2014 164Number of
Products by Stage and Top 10 Routes of
Administration, H2 2014 164
8Browse Full Report
- Or Sample Request _at_
- http//www.aarkstore.com/pharmaceuticals-healthcar
e/60608/type-1-diabetes-juvenile-diabetes-pipeline
-review-h2-2014
9Related Reports
- Fabry Disease-Pipeline Insights, 2015
- Ocular Hypertension-Pipeline Insights, 2015
- Fallopian Tube Cancer-Pipeline Insights, 2015
- Ocular Inflammation-Pipeline Insights, 2015
- Familial Adenomatous Polyposis Coli-Pipeline
Insights, 2015 - Ocular Pain-Pipeline Insights, 2015
- Familial Amyloid Polyneuropathy (Transthyretin
Amyloidosis, Corino de Andrades Disease)-Pipeline
Insights, 2015 - Oligodendroglioma-Pipeline Insights, 2015
10Follow Us
https//www.facebook.com/aarkstoredotcom
https//twitter.com/aarkstore
https//plus.google.com/Aarkstoredotcom/posts
https//www.linkedin.com/company/aarkstore-enterpr
ise
11Contact Us
Office Address Office No. - 809, 8th
Floor,B-Wing, Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Mail us at
contact_at_aarkstore.com 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953